Pipeline

ZyVersa's mission is to develop novel, first-in-class drugs that optimize health outcomes and improve patients' quality of life. Our evolving product pipeline is targeted at anti-inflammatory and renal diseases.

Pipeline

For treatment of inflammatory diseases, our highly differentiated monoclonal antibody, IC 100, inhibits inflammasome ASC. Unlike NLRP3 inhibitors, which target only the NLRP3 inflammasome, by targeting ASC, IC 100 potentially inhibits twelve or more inflammasomes. This is expected to better control inflammation in numerous inflammatory diseases that are triggered by activation of more than one type of inflammasome. Likewise, by targeting ASC, IC 100 inhibits inflammasome formation and initiation of the inflammatory cascade. It also inhibits extracellular ASC specks to attenuate propagation and systemic spread of inflammation that leads to comorbidities. The lead indication for IC 100 is cardiometabolic conditions, with indication expansion potential in orphan renal diseases and other CNS and peripheral inflammatory diseases.

For treatment of renal diseases, VAR 200 targets a key unaddressed pathway – renal lipotoxicity. VAR 200 mediates removal of pathogenic cholesterol and other lipids that accumulate in the kidneys’ filtration system causing structural and functional damage and disease progression. VAR 200 is expected to be added to standard of care RAS inhibitors and immunosuppressants to better control proteinuria and reduce disease progression. The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS), an orphan renal disease, with indication expansion potential into Alport syndrome and diabetic kidney disease.